(S009) Radiation Therapy Improves Outcomes With Desmoplastic Melanoma of the Head and Neck

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Radiotherapy improves both local and locoregional control in patients with desmoplastic melanoma of the head and neck, regardless of margin status.

Tobin J. Strom, MD, Jimmy J. Caudell, MD, PhD, Jonathan S. Zager, MD, C. Wayne Cruse, MD, Jane L. Messina, MD, Vernon K. Sondak, MD, Louis B. Harrison, MD, Andy M. Trotti, MD; H. Lee Moffitt Cancer Center and Research Institute

BACKGROUND: Desmoplastic melanomas are considered to have a high risk of local recurrence after resection alone, especially in the head and neck. We hypothesized that adjuvant radiotherapy might reduce the risk of local recurrence.

METHODS: A single-institution institutional review board (IRB)-approved study was performed including 140 patients with desmoplastic melanoma without distant metastatic disease treated from 1990–2010 with wide excision ± sentinel lymph node dissection ± regional lymph node dissection. Patient, tumor, and treatment characteristics were compared between the groups based on receipt of adjuvant radiotherapy. Adjuvant radiotherapy was delivered to the primary tumor bed in all cases with a 2–4-cm margin as feasible and to the draining lymphatics in a minority of cases (n = 5). Patients were treated to a total dose of either 30 Gy in 5-Gy fractions dosed twice per week (n = 37) or 50–68 Gy in 25–34 daily fractions (n = 32). Adjuvant systemic therapy was delivered in 18 cases (interferon in 16 of 18 cases). The primary study outcome was local control, and the secondary outcome was locoregional control. Kaplan-Meier (KM) analysis and the log-rank test were used to compare outcomes. A Cox hazards multivariate (MV) model was created for the primary outcome.

RESULTS: Median follow-up was 47 months. Receipt of radiotherapy was associated with deeper tumors (median 5.4 mm vs 2.8 mm; P < .001) and positive margins (28% vs 13%; P = .03), compared with no radiotherapy. Nevertheless, adjuvant radiotherapy was associated with improved local control compared with patients who did not receive it (4-yr KM estimate: 94% vs 74%; P = .02) and locoregional control (4-yr KM estimate: 86% vs 69%; P = .03). On Cox MV analysis, radiotherapy was independently associated with improved local control (hazard ratio [HR] = 0.17; 95% confidence interval [CI], 0.06–0.51]; P = .002) and locoregional control (HR = 0.26; 95% CI, 0.11–0.63; P = .003). Variables associated with local recurrence on MV analysis included age > 70 years (HR = 4.1; 95% CI, 1.6–10.6; P = .004) and positive margins (HR = 5.6; 95% CI, 2.1–15.1; P = .001). Among patients with positive margins (n = 28), those treated with radiation therapy had improved local control (4-yr KM estimate: 88% vs 18%; P = .01) compared with those not treated with adjuvant radiation. Similarly, patients who had negative margins also benefited from adjuvant radiation therapy (4-yr KM local control estimate: 96% vs 80%; P = .048). 

CONCLUSIONS: Radiotherapy improves both local and locoregional control in patients with desmoplastic melanoma of the head and neck, regardless of margin status.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content